Rheumatology Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Intracranial giant cell arteritis: a comprehensive systematic review. 2025
• Ocular manifestations of ANCA-associated vasculitis 2023
• Causal pathways to health-related quality of life in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort 2021
• Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis 2019
• A CLINICAL SCORING SYSTEM FOR RISK STRATIFICATION OF GIANT CELL ARTERITIS 2019
• COMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASU'S ARTERITIS AND GIANT CELL ARTERITIS 2019
• DIFFUSE ALVEOLAR HEMORRHAGE, PULMONARY NODULES AND INFILTRATES IN GRANULOMATOSIS POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. A COHORT STUDY OF 736 PATIENTS 2019
• FACTORS ASSOCIATED WITH DISEASE PROGRESSION IN PATIENTS WITH MYELOPEROXIDASE-ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-RELATED PULMONARY FIBROSIS 2019
• GENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE 2019
• THE EFFECT OF PLASMA EXCHANGE ON END-STAGE RENAL DISEASE AND DEATH IN PATIENTS WITH SEVERE ANCA-ASSOCIATED VASCULITIS 2019
• THE EFFECT OF REDUCED-DOSE ORAL GLUCOCORTICOIDS DURING INDUCTION OF REMISSION INDUCTION IN SEVERE ANCA-ASSOCIATED VASCULITIS 2019
• UTILIZATION OF CANADIAN HEALTHCARE ADMINISTRATIVE DATABASES TO ACCURATELY IDENTIFY CASES OF ANCA-ASSOCIATED VASCULITIS 2019
• VERITAS: VASCULITIS: EFFECTS OF REMISSION MAINTENANCE THERAPIES ON RELAPSE AND SIDE EFFECTS ON PATIENT PREFERENCES: A STUDY PROTOCOL 2019
• A RANDOMIZED DOUBLE-BLIND TRIAL OF ABATACEPT AND GLUCOCORTICOIDS FOR THE TREATMENT OF TAKAYASU'S ARTERITIS 2017
• ARTERIAL LESIONS IN GIANT CELL ARTERITIS 2017
• DEMOGRAPHIC CHARACTERISTICS OF JAPANESE PARTICIPANTS IN PEXIVAS AS COMPARED WITH REMIT-JAV 2017
• DISCREPANCIES BETWEEN CLINICAL- AND IMAGING-BASED ASSESSMENTS OF DISEASE ACTIVITY IN TAKAYASU'S ARTERITIS 2017
• IDENTIFICATION OF FUNCTIONAL AND EXPRESSION POLYMORPHISMS ASSOCIATED WITH RISK FOR ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY-ASSOCIATED VASCULITIS 2017
• LATE-ONSET RELAPSE IN PATIENTS WITH SYSTEMIC VASCULITIS 2017
• PATIENT REPORTED OUTCOMES AS PREDICTORS OF FLARES IN TAKAYASU ARTERITIS 2017
• PLASMA EXCHANGE AND GLUCOCORTICOID DOSING IN THE TREATMENT OF ANTI-NEUTROPHIL CYTOPLASM ANTIBODY ASSOCIATED VASCULITIS: BASELINE CHARACTERISTICS OF A RANDOMIZED CONTROLLED TRIAL (PEXIVAS) 2017
• PREVALENCE OF IMMUNOFLUORESCENT DEPOSITS IN ANCA ASSOCIATED VASCULITIS 2017
• SPUTUM ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (ANCA) IN EOSINOPHILIC GRANULAMATOSIS AND POLYANGIITIS (EGPA) 2017
• THE STEROID TAPERING IN ANCA VASCULITIS EVALUATION STUDY (STAVE) 2: A SYSTEMATIC REVIEW AND META-ANALYSIS 2017
• TWO INTERNATIONAL MULTIREGIONAL INVESTIGATOR INITIATED CLINICAL TRIALS ON VASCULITIS: COLLABORATION WITH EUVAS, VCRC AND NATIONWIDE VASCULITIS STUDY GROUPS OF JAPAN 2017
• URINARY EPIDERMAL GROWTH FACTOR AS A BIOMARKER OF RENAL INVOLVEMENT IN ANCA-ASSOCIATED VASCULITIS 2017
• UTILITY OF MEASUREMENTS OF URINARY SOLUBLE CD163 & MCP1 IN THE IDENTIFICATION OF SUBTLE RENAL FLARES IN ANCA VASCULITIS 2017
• Gout in paleopathology; The elusive nature of urate 2007
• Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial..  64:3863-3871. 2025
• Fatigue levels and associated factors in systemic sclerosis: a cross-sectional study of 2385 SPIN Cohort participants..  64:2810-2820. 2025
• Vessel wall MRI in giant cell arteritis: standardized protocol and scoring approach developed by an international working group..  64:2910-2918. 2025
• Does plasma exchange have a role in ANCA-associated vasculitis? Viewpoint 1: plasma exchange should not be used indiscriminately..  64:i64-i67. 2025
• Assessment of damage in Takayasu’s arteritis.  64:682-689. 2025
• Factors associated with physical function among people with systemic sclerosis: a SPIN cohort cross-sectional study.  63:2660-2669. 2024
• Lung imaging patterns in connective tissue disease–associated interstitial lung disease impact prognosis and immunosuppression response.  63:2734-2740. 2024
• A decade of progress in juvenile idiopathic arthritis treatments and outcomes in Canada: results from ReACCh-Out and the CAPRI registry.  63:SI173-SI179. 2024
• The effect of antimalarials on the safety and persistence of treatment with biologic agents or Janus kinase inhibitors in rheumatoid arthritis.  63:456-465. 2024
• Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM.  62:2989-2997. 2023
• CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum.  62:2646-2651. 2023
• Added diagnostic yield of temporal artery magnetic resonance angiography in the evaluation of giant cell arteritis.  62:2197-2202. 2023
• Comment on: Text neck misdiagnosed as fibromyalgia..  62:e199-e200. 2023
• Comparing Canadian paediatric rheumatology practice to the 2019 ACR Juvenile Idiopathic Arthritis guidelines: results from the CAPRI Registry.  62:1616-1620. 2023
• Validation of the parent global assessment as a health-related quality of life measure in juvenile idiopathic arthritis: results from ReACCh-Out.  62:SI152-SI162. 2023
• Trends in risk factor control in patients with gout: data from the National Health and Nutrition Examination Survey, 2007–2018.  62:158-168. 2022
• Hypothyroidism in vasculitis.  61:2942-2950. 2022
• Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.  61:SI143-SI150. 2022
• Impact of the COVID-19 pandemic on juvenile idiopathic arthritis presentation and research recruitment: results from the CAPRI registry.  61:SI157-SI162. 2022
• Incidence of chronic immune-mediated inflammatory diseases after diagnosis with Kawasaki disease: a population-based cohort study.  61:2095-2103. 2022
• Impact of the COVID-19 Pandemic on Juvenile Idiopathic Arthritis Presentation and Research Recruitment: Results from the CAPRI Registry (135/140)..  49:800-800. 2021
• Contextualizing temporal arterial magnetic resonance angiography in the diagnosis of giant cell arteritis: a retrospective cohort study.  60:4229-4237. 2021
• Comment on: Influence of prior antibiotic use on risk of rheumatoid arthritis: case–control study in general practice. Reply.  60:e150-e150. 2021
• Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes.  60:617-628. 2021
• Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis.  60:73-80. 2021
• Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience.  59:3727-3730. 2020
• Patients’ attitudes and experiences of transition from paediatric to adult healthcare in rheumatology: a qualitative systematic review.  59:3737-3750. 2020
• Corrigendum to: Incidence and prevalence of giant cell arteritis in Ontario, Canada.  59:3584-3584. 2020
• Incidence and prevalence of giant cell arteritis in Ontario, Canada.  59:3250-3258. 2020
• A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry.  59:2796-2805. 2020
• Influence of prior antibiotic use on risk of rheumatoid arthritis: case control study in general practice.  59:1281-1287. 2020
• Derivation of an angiographically based classification system in Takayasu’s arteritis: an observational study from India and North America.  59:1118-1127. 2020
• Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity.  59:398-406. 2020
• Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.  58:636-644. 2019
• 020. IDENTIFICATION OF TARGET ANTIGENS FOR ANTI-ENDOTHELIAL CELL ANTIBODIES IN PATIENTS WITH TAKAYASU’S ARTERITIS USING PROTEOMICS.  58:kez057.019. 2019
• 035. CANDIDATE BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS IDENTIFIED USING A PROTEOMIC APPROACH.  58:kez057.034. 2019
• 043. SUBGLOTTIC STENOSIS AND ENDOBRONCHIAL DISEASE IN GRANULOMATOSIS WITH POLYANGIITIS.  58:kez057.042. 2019
• 045. EVALUATION OF NOVEL SERUM BIOMARKERS OF DISEASE ACTIVITY IN GIANT CELL ARTERITIS, TAKAYASU’S ARTERITIS, POLYARTERITIS NODOSA, AND EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS.  58:kez057.044. 2019
• 083. COMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASU’S ARTERITIS AND GIANT CELL ARTERITIS.  58:kez058.023. 2019
• 084. DISCOVERY AND VALIDATION OF A NOVEL ANGIOGRAPHIC CLASSIFICATION SCHEME IN TAKAYASU’S ARTERITIS.  58:kez058.024. 2019
• 090. A CLINICAL SCORING SYSTEM FOR RISK STRATIFICATION OF GIANT CELL ARTERITIS.  58:kez058.030. 2019
• 138. DIFFUSE ALVEOLAR HEMORRHAGE, PULMONARY NODULES AND INFILTRATES IN GRANULOMATOSIS POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. A COHORT STUDY OF 736 PATIENTS.  58:kez059.015. 2019
• 139. UTILIZATION OF CANADIAN HEALTHCARE ADMINISTRATIVE DATABASES TO ACCURATELY IDENTIFY CASES OF ANCA-ASSOCIATED VASCULITIS.  58:kez059.016. 2019
• 148. SHORT-FORM 36 AS A MEASURE OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GIANT CELL ARTERITIS.  58:kez059.025. 2019
• 160. VERITAS: VASCULITIS: EFFECTS OF REMISSION MAINTENANCE THERAPIES ON RELAPSE AND SIDE EFFECTS ON PATIENT PREFERENCES: A STUDY PROTOCOL.  58:kez059.037. 2019
• 275. FACTORS ASSOCIATED WITH DISEASE PROGRESSION IN PATIENTS WITH MYELOPEROXIDASE-ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-RELATED PULMONARY FIBROSIS.  58:kez062.049. 2019
• Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome.  58:103-109. 2019
• Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review.  57:1802-1811. 2018
• The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts.  57:1623-1631. 2018
• Evaluation of damage in giant cell arteritis.  57:322-328. 2018
• Evaluating the design and reporting of pragmatic trials in osteoarthritis research.  57:59-63. 2018
• Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.  56:1111-1122. 2017
• The effect of rheumatoid arthritis–associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis.  56:kew474-kew474. 2017
• Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues.  56:kew441-kew441. 2017
• P1_185 The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: a Systematic Review and Meta-Analysis.  56:iii103-iii103. 2017
• WS1_1 Sputum Anti-neutrophil Cytoplasmic Antibodies (ANCA) in Eosinophilic Granulamatosis and Polyangiitis (eGPA).  56:iii17-iii19. 2017
• BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.  56:313-316. 2017
• Calcinosis is associated with digital ischaemia in systemic sclerosis—a longitudinal study.  55:2148-2155. 2016
• Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort.  55:1751-1762. 2016
• Lysophosphatidylcholines to phosphatidylcholines ratio predicts advanced knee osteoarthritis..  55:1566-1574. 2016
• Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis.  54:1351-1359. 2015
• Comment on: A critical evaluation of the trigger point phenomenon.  54:1126-1127. 2015
• What drives the comparative effectiveness of biologics vs methotrexate in rheumatoid arthritis? Meta-regression and graphical inspection of suspected clinical factors.  53:1264-1273. 2014
• Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort.  53:1075-1086. 2014
• The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis.  53:821-827. 2014
• Unilateral vs bilateral symptomatic knee osteoarthritis: associations between pain intensity and function.  52:2229-2237. 2013
• All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre.  52:905-909. 2013
• Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patients.  51:1887-1893. 2012
• von Willebrand factor antigen--a possible biomarker of disease activity in childhood central nervous system vasculitis?.  51:1838-1845. 2012
• Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone.  51:571-576. 2012
• Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation.  49:837-843. 2010
• Investigating the role of the interleukin-23/-17A axis in rheumatoid arthritis.  48:1581-1589. 2009
• Intrinsic pathway of apoptosis in peripheral blood eosinophils of Churg–Strauss syndrome.  48:1202-1207. 2009
• Reports of abnormal cervical cancer screening tests in systemic sclerosis.  48:149-151. 2009
• Quality of randomized clinical trials in juvenile idiopathic arthritis.  47:640-645. 2008
• Arthritis risk after acute bacterial gastroenteritis.  47:200-204. 2008
• Developing a disease activity tool for systemic-onset juvenile idiopathic arthritis by international consensus using the Delphi approach.  44:1574-1578. 2005
• What does ‘active disease’ mean? patient and parent perceptions of disease activity in the systemic arthritis form of juvenile idiopathic arthritis (SO-JIA).  44:796-799. 2005
• Acupuncture for the alleviation of lateral epicondyle pain: a systematic review.  43:1085-1090. 2004
• Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience.  43:992-999. 2004
• Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate.  43:712-718. 2004
• Doctor-patient communication in a musculoskeletal unit: relationship between an observer-rated structured scoring system and patient opinion.  42:1518-1522. 2003
• Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals.  42:263-267. 2003
• Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis.  41:A473-474. 2002
• Characteristics of septic arthritis in human immunodeficiency virus- infected haemophiliacs versus other risk groups.  38:139-142. 1999
• Auranofin.  36:560-572. 1997
• Salmon calcitonin nasal spray in the prevention of corticosteroid- induced osteoporosis.  36:255-259. 1997
• SENSITIVITY AND SPECIFICITY OF DIFFERENT DIAGNOSTIC CRITERIA FOR BEHÇET'S DISEASE ACCORDING TO THE LATENT CLASS APPROACH.  34:932-935. 1995
• Cyclosporin A nephropathy in patients with rheumatoid arthritis..  32 Suppl 1:60-64. 1993
• Successful Treatment of Gold-induced Aplastic Anaemia with Granulocyte Macrophage Colony Stimulating Factor.  31:428-429. 1992
• Prior Score Availability: Observations Using The WOMAC Osteoarthritis Index.  30:150-151. 1991
• INTERACTION OF IBUPROFEN AND WARFARIN ON PRIMARY HAEMOSTASIS.  28:46-49. 1989
• PUNCHED-CARD AID IN RHEUMATOLOGICAL DIAGNOSIS.  26:46-50. 1987

has subject area

• 1103 Clinical Sciences (FoR)
• 1107 Immunology (FoR)
• 1117 Public Health and Health Services (FoR)
• Arthritis & Rheumatology (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 0263-7103
• 1462-0324

Electronic International Standard Serial Number (EISSN)

• 1460-2172
• 1462-0332